Shares in Sphere Medical (LON:SPHR) spiked 5% after it said it had received the final approval that paves the way for the commercial launch of its breakthrough blood monitor later this year. The group has attained its CE mark under the EU Medical Devices Directive, which means its Proxima system complies with European product legislation. In all it has four CE marks. The company in a statement said it will go ahead with what it called a post market clinical follow-up study, which will be carried out at the Queen Elizabeth Hospital in Birmingham, as well as heading into the full commercial launch of Proxima.
Help employers find you! Check out all the jobs and post your resume.
